RxDoctor Payments Data

Princewill Ogbuji, MD

Cardiovascular Disease · Valatie, NYNPI 1750341897

Payments from drug & device makers

$928in general payments, 2019–2025

Across 30 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$353
  • Johnson & Johnson$150
  • Medtronic$116
  • Edwards Lifesciences$106
  • Pfizer$91
  • AstraZeneca$53
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$91499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$928 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$94,921
Medicare patients
552
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban380$387,970
XareltoRivaroxaban51$49,590
EntrestoSacubitril/Valsartan46$46,972
FarxigaDapagliflozin Propanediol32$24,271
Repatha SyringeEvolocumab23$22,086
Repatha SureclickEvolocumab27$17,619
Ranolazine ErRanolazine57$8,727
Metoprolol Succinate319$3,826
BenicarOlmesartan Medoxomil13$2,803
Atorvastatin Calcium180$2,173
Digoxin92$1,979
Metoprolol Tartrate211$1,374
Isosorbide Dinitrate12$1,190
Warfarin Sodium90$1,092
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$387,970380 claims
Johnson & JohnsonXarelto$150$49,59051 claims
NovartisEntresto$12$46,97246 claims
AstraZenecaFarxiga$53$24,27132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Valatie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →